However, many further problems also occur: (a) the great capacity of tumour tissues for shifting their metabolic profile to adapt and survive the therapeutic conditions in the presence of diverse microenvironments [28] and (b) the insufficient cost-benefit in tolerance of therapeutic efficacy and side-effect toxicity in patients (many promising drugs, especially mTOR, glutaminolysis or glycolysis inhibitors have been failed in clinical trials recently). The gene discussed is MTOR; the disease is neoplasm.